BASKING RIDGE, N.J. , Jan. 28, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq:ECOR), a commercial-stage bioelectronic medicine company, today announced Chief Executive Officer, Frank Amato and Chief Science & Strategy Officer, JP Errico will present at NobleConXV - Noble
BASKING RIDGE, N.J. , Jan. 08, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced two clinical studies focused on expanding the use of non-invasive vagus nerve stimulation (nVNS) for the acute and preventive treatment of
BASKING RIDGE, N.J. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced its non-invasive vagus nerve stimulation (nVNS) therapy, gammaCore TM , has been awarded a five-year Federal Supply Schedule Medical Equipment
BASKING RIDGE, N.J. , Nov. 28, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it received 510(k) clearance from the U.S. Food and Drug Administration ( FDA ) for an expanded label for gammaCore™ [non-invasive vagus
BASKING RIDGE, N.J. , Nov. 27, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq:ECOR), a commercial-stage bioelectronic medicine company, today announced expansion into a new design and development facility to support increasing patient demand of its gammaCore™ non-invasive vagus
BASKING RIDGE, N.J. , Nov. 20, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the company will be participating in the upcoming Evercore ISI HealthCONx Conference in Boston, MA.
BASKING RIDGE, N.J. , Nov. 13, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“ electroCore”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today reported financial results for the three months and nine months ended September 30, 2018 .
Report contributors agreed gammaCore was highly innovative, may be more effective than standard of care alone, and has the potential to save money through the NHS by reducing the cost of treating cluster headache BASKING RIDGE, N.J. , Nov. 09, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc.,
BASKING RIDGE, N.J. , Oct. 30, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it will release financial results for the third quarter ended September 30, 2018 after the close of trading on Tuesday,
BASKING RIDGE, N.J. , Oct. 30, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq:ECOR), a commercial-stage bioelectronic medicine company, today announced the appointment of Ardelle Ferris to a new position within the company, Vice President of Managed Care.